New study provides strong evidence for role of Epstein Barr virus as a trigger for multiple sclerosis
14 January 2022
New research has provided evidence that infection with the Epstein Barr virus acts as a trigger for people to develop MS.
Ponvory (ponesimod) approved for relapsing remitting MS in England and Wales
23 December 2021
The MS Trust is delighted that Ponvory (ponesimod) has been approved in England and Wales for people with active relapsing remitting multiple sclerosis.
The PANORAMIC trial for Covid-19 treatment
23 December 2021
If you are not eligible to receive Covid-19 treatment automatically on the basis of increased risk, you may be able to get antiviral medication through the PANORAMIC clinical trial.
Covid-19 treatments for people with MS
22 December 2021
People with MS can get effective treatments if they get Covid-19. This article explains more about molnupiravir (Lagevrio) and sotrovimab (Xetrudy) and how to get them if you catch coronavirus.
Fampyra rejected in draft update to NICE MS Clinical Guideline
17 December 2021
NICE has rejected Fampyra (fampridine) as an NHS treatment for people with MS-related walking problems in the draft of the updated multiple sclerosis clinical guideline.
Ponvory (ponesimod) approved for relapsing remitting MS in Scotland
10 November 2021
The MS Trust is delighted that Ponvory (ponesimod) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.
Temelimab: early clinical trial suggests potential for remyelination
26 October 2021
Results from an early stage clinical trial suggests that temelimab may promote remyelination and prevent loss of nerve cells.
Ponesimod (Ponvory) for relapsing remitting multiple sclerosis rejected by NICE
13 October 2021
The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.
Multiple sclerosis and disease modifying drugs, what are my options?
28 September 2021
We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.
New report highlights barriers to accessing Sativex across the UK
18 August 2021
Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.
How does MS affect dating and romantic relationships?
2 August 2021
This study took an in-depth look at the dating experiences of a small group of people living with MS.
Kesimpta (ofatumumab) approved for relapsing remitting MS in Scotland
12 July 2021
The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.